CN102499996A - Fibrous membrane for non-virus gene treatment and preparation method thereof - Google Patents
Fibrous membrane for non-virus gene treatment and preparation method thereof Download PDFInfo
- Publication number
- CN102499996A CN102499996A CN2011103448745A CN201110344874A CN102499996A CN 102499996 A CN102499996 A CN 102499996A CN 2011103448745 A CN2011103448745 A CN 2011103448745A CN 201110344874 A CN201110344874 A CN 201110344874A CN 102499996 A CN102499996 A CN 102499996A
- Authority
- CN
- China
- Prior art keywords
- fibrous membrane
- growth factor
- dissolved
- organic polymer
- viral gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a fibrous membrane which is applied to tissue engineering mediated non-virus gene treatment and preparation method thereof. The fibrous membrane comprises an organic high polymer, growth factors and a small molecular pore-forming agent, and is prepared by performing electrostatic spinning on an outer layer organic high polymer solution and an inner layer growth factor solution by needle heads which are arranged in a concentric mode and have different diameters, wherein the small molecular pore-forming agent is added into the outer layer organic high polymer solution. The fibrous membrane has the advantages that: a composite fiber material with a nuclear-shell structure is prepared by a coaxial electrostatic spinning method, so that the encapsulating rate of electric spinning fibers is improved, and the bioactivity of the growth factors can be kept for a long time; the sustained release of the growth factors is facilitated by the small molecular pore-forming agent, and blood coagulation factors can be released stably for a long time; and various growth factors can promote tissues and designed skeletal muscles to be well integrated, so that an effect of treating A type hemophilia for a long time is achieved, and the fibrous membrane can be applied to the tissue engineering mediated non-virus gene treatment.
Description
Technical field:
The present invention relates to organizational project fibrous membrane and preparation method thereof, relate in particular to a kind of non-viral gene treatment fibrous membrane that is applied to the organizational project mediation and preparation method thereof.
Background technology:
Haemophilia A is a kind of X hereditary, causes lacking blood coagulation factor VIII (FVIII) in the body, and this is a kind of cofactor that in the coagulation cascade process, plays a key effect, and the Stuart factor Proteolytic enzyme is activated be Xa factor.At present, hemophiliac all needs regularly to inject recombinant plasma blood coagulation factor VIII concentrated solution all one's life, and the viral gene therapy has obtained gratifying achievement at preclinical phase and I clinical trial phase, but faces the restriction of T-cell mediated immune response.
Skeletal myoblast is the blast cell of one type of specific muscles cell, can be used for gene therapy, and very big application potential is arranged.Sarcoplast is responsible for growth, reparation and the regeneration of regulation and control skeletal muscle usually, and its life-span is longer, is fit to carry out external expansion and genetic engineering.Yet, according to experience in the past, be injected into human body after, myoblastic survival ability is lower.
The research proof, the fiber pattern of marshalling can induce sarcoplast along fiber growth, raises the film stretching, active ions passage and the differentiation of promotion apocyte.People can arrange myotube and integrate support, the myofibrillar structure of its board structure parody endoskeleton according to the fibre base plate structure.But owing to lack blood vessel and lymphatic vessel and neutral net, simple can not integrate with in-vivo tissue at body implantation Bionic Design tissue comprehensively.
Summary of the invention:
The object of the present invention is to provide a kind of non-viral gene treatment fibrous membrane that is applied to the organizational project mediation and preparation method thereof.
To achieve these goals, the present invention proposes following technical scheme realization:
A kind of fibrous membrane that is used for the non-viral gene treatment; It is characterized in that: fibrous membrane comprises organic polymer, somatomedin and micromolecule porogen; Wherein fibrous membrane through outer organic polymer solution and internal layer growth factor solution respectively the syringe needle through the different-diameter arranged with concentric manner carry out electrostatic spinning and process, in outer organic polymer solution, add the micromolecule porogen simultaneously.
Described organic polymer weight average molecular weight is 5-30 ten thousand, is selected from polyurethanes, polyvinyl acetate, PEO, polyvinyl alcohol, polylactic acid and polycaprolactone.
Described somatomedin is selected from lymphatic vessel somatomedin, human vascular endothelial growth factor A, epidermal growth factor, somatostatin and human blood platelets derivative growth factor-BB.
Described micromolecule porogen is a Polyethylene Glycol.
A kind of fibrous membrane method for preparing that is used for the non-viral gene treatment may further comprise the steps:
(1) be dissolved in inorganic somatomedin or organic solvent, being mixed with concentration is the internal layer growth factor solution of 0.01-1mg/ml;
(2) the water-soluble or organic solvent with organic polymer, being mixed with mass percentage concentration is the outer organic polymer solution of 2-30%, and adding molecular weight simultaneously is the micromolecule porogen Polyethylene Glycol of 2000-6000, and concentration is 0.1-1.0%W/V;
The syringe needle of (3) two kinds of different-diameters is arranged with concentric mode and is carried out spinning; Interior shaft diameter 0.1-1mm; Outer shaft diameter 3-5mm, the speed of internal layer growth factor solution is 0.1-2mL/h, the speed of outer organic polymer solution is 5-8mL/h; Distance between syringe needle and the rotation wheel is 10-20cm, and voltage is 10-30KV.
The pairing solvent of described somatomedin is respectively: the lymphatic vessel somatomedin is dissolved in acetone or sour microcosmic salt buffer; Human vascular endothelial growth factor A is dissolved in phosphate buffer or phosphate buffer and DMSO mixed liquor; Water-soluble or the dimethyl formamide of epidermal growth factor; Somatostatin is dissolved in the mixed liquor of dimethyl sulfoxide or dimethyl sulfoxide and water; Human blood platelets derivative growth factor-BB is dissolved in phosphate buffer or acetone.
The pairing solvent of described organic polymer is respectively: polyvinyl acetate is dissolved in dimethyl formamide; PEO is water-soluble; The mixed liquor of polyvinyl alcohol water-soluble or acetone or water and acetone; Polylactic acid is dissolved in the mixed liquor of dimethyl formamide or dimethyl formamide and acetone; Polyurethanes is dissolved in chloroform and alcoholic acid mixed liquor; Polycaprolactone is dissolved in acetone or oxolane.
Beneficial effect of the present invention: utilize the method for coaxial electrostatic spinning to prepare the nucleocapsid structure complex fiber material; Improved the envelop rate of electrospinning fibre; Can keep the somatomedin biological activity for a long time, and the micromolecule porogen is beneficial to the slow release of somatomedin, can discharges thrombin steadily in the long term; Various somatomedin can promote the good integration of skeletal muscle organizing and design; Thereby reach the effect of long-term treatment haemophilia A, technology is simple, easy operating and cost are low, can be applicable to the non-viral gene treatment of organizational project mediation.
The specific embodiment:
Below describe preferred implementation of the present invention, but be not in order to limit the present invention.
Embodiment 1:
Be used for non-viral gene treatment fibrous membrane according to following method preparation:
(1) preparation internal layer growth factor solution: with 1 milligram of somatomedin (VEGFC), or VEGFA (VEGF-A165) and PDGF-BB are dissolved in 100ml phosphate-buffered liquor (PBS) as internal layer solution.
(2) prepare outer organic polymer solution: the chloroform that polyurethane is dissolved in 75: 25 (V/V) ratios: ethanol; Be mixed with mass percentage concentration and be 25% macromolecular solution; Add molecular weight simultaneously and be 3400 micromolecule porogen Polyethylene Glycol, its concentration is that 0.7% (W/V) is as internal layer solution.
(3) preparation complex fiber material: the syringe needle of two kinds of different-diameters is arranged with concentric mode; Interior shaft diameter 0.5mm; Outer shaft diameter 3mm, so that can distribute two kinds of solution simultaneously, the speed of internal layer solution is that the speed of 1mL/h and outer solution is 6mL/h; Distance between syringe needle and the rotation wheel is 15cm, and voltage is 20KV.
Claims (7)
1. one kind is used for the fibrous membrane that non-viral gene is treated; It is characterized in that: fibrous membrane comprises organic polymer, somatomedin and micromolecule porogen; Wherein fibrous membrane through outer organic polymer solution and internal layer growth factor solution respectively the syringe needle through the different-diameter arranged with concentric manner carry out electrostatic spinning and process, in outer organic polymer solution, add the micromolecule porogen simultaneously.
2. a kind of fibrous membrane that is used for the non-viral gene treatment according to claim 1; It is characterized in that: described organic polymer weight average molecular weight is 5-30 ten thousand, is selected from polyurethanes, polyvinyl acetate, PEO, polyvinyl alcohol, polylactic acid and polycaprolactone.
3. a kind of fibrous membrane that is used for the non-viral gene treatment according to claim 1, it is characterized in that: described somatomedin is selected from lymphatic vessel somatomedin, human vascular endothelial growth factor A, epidermal growth factor, somatostatin and human blood platelets derivative growth factor-BB.
4. a kind of fibrous membrane that is used for the non-viral gene treatment according to claim 1, it is characterized in that: described micromolecule porogen is a Polyethylene Glycol.
5. one kind is used for the fibrous membrane method for preparing that non-viral gene is treated, and may further comprise the steps:
(1) be dissolved in inorganic somatomedin or organic solvent, being mixed with concentration is the internal layer growth factor solution of 0.01-1mg/ml;
(2) the water-soluble or organic solvent with organic polymer, being mixed with mass percentage concentration is the outer organic polymer solution of 2-30%, and adding molecular weight simultaneously is the micromolecule porogen Polyethylene Glycol of 2000-6000, and concentration is 0.1-1.0%W/V;
The syringe needle of (3) two kinds of different-diameters is arranged with concentric mode and is carried out spinning; Interior shaft diameter 0.1 1 1mm; Outer shaft diameter 3-5mm, the speed of internal layer growth factor solution is 0.1-2mL/h, the speed of outer organic polymer solution is 5-8mL/h; Distance between syringe needle and the rotation wheel is 10-20cm, and voltage is 10-30KV.
6. a kind of fibrous membrane method for preparing that is used for the non-viral gene treatment according to claim 5, it is characterized in that: the pairing solvent of described somatomedin is respectively: the lymphatic vessel somatomedin is dissolved in acetone or sour microcosmic salt buffer; Human vascular endothelial growth factor A is dissolved in phosphate buffer or phosphate buffer and DMSO mixed liquor; Water-soluble or the dimethyl formamide of epidermal growth factor; Somatostatin is dissolved in the mixed liquor of dimethyl sulfoxide or dimethyl sulfoxide and water; Human blood platelets derivative growth factor-BB is dissolved in phosphate buffer or acetone.
7. a kind of fibrous membrane method for preparing that is used for the non-viral gene treatment according to claim 5, it is characterized in that: the pairing solvent of described organic polymer is respectively: polyvinyl acetate is dissolved in dimethyl formamide; PEO is water-soluble; The mixed liquor of polyvinyl alcohol water-soluble or acetone or water and acetone; Polylactic acid is dissolved in the mixed liquor of dimethyl formamide or dimethyl formamide and acetone; Polyurethanes is dissolved in chloroform and alcoholic acid mixed liquor; Polycaprolactone is dissolved in acetone or oxolane.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103448745A CN102499996A (en) | 2011-11-04 | 2011-11-04 | Fibrous membrane for non-virus gene treatment and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011103448745A CN102499996A (en) | 2011-11-04 | 2011-11-04 | Fibrous membrane for non-virus gene treatment and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102499996A true CN102499996A (en) | 2012-06-20 |
Family
ID=46212169
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011103448745A Pending CN102499996A (en) | 2011-11-04 | 2011-11-04 | Fibrous membrane for non-virus gene treatment and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102499996A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104027848A (en) * | 2014-06-24 | 2014-09-10 | 中国人民解放军第四军医大学 | Biological scaffold material for periodontium and preparation method thereof |
| CN104474589A (en) * | 2014-12-23 | 2015-04-01 | 山东国际生物科技园发展有限公司 | Guided tissue regeneration membrane as well as preparation method and application thereof |
| CN104491932A (en) * | 2014-12-04 | 2015-04-08 | 上海工程技术大学 | Drug-loaded nanometer anti-adhesion membrane having core/shell structure and preparation method thereof |
| CN110468469A (en) * | 2019-09-03 | 2019-11-19 | 黑龙江中医药大学 | One seed coat layer sandwich layer containing pore-foaming agent carries the preparation method of the coaxial electrostatic spinning silk fiber of medicine |
| EP3981443A1 (en) * | 2020-10-08 | 2022-04-13 | Johann Wolfgang Goethe-Universität Frankfurt | Improved wound dressings, methods for making these, and uses thereof |
| CN114984295A (en) * | 2022-04-14 | 2022-09-02 | 广东云曌医疗科技有限公司 | Porous nano medical dressing and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6350284B1 (en) * | 1998-09-14 | 2002-02-26 | Bionx Implants, Oy | Bioabsorbable, layered composite material for guided bone tissue regeneration |
| CN1727530A (en) * | 2005-07-26 | 2006-02-01 | 天津大学 | Superfine fiber membrane material in core/shell structure, and preparation method |
| CN1733311A (en) * | 2005-08-18 | 2006-02-15 | 同济大学 | The preparation method of the nanofiber of a kind of packaging medicine or somatomedin |
| US7648665B2 (en) * | 2002-12-23 | 2010-01-19 | Microcell Corporation | Substrate-supported process for manufacturing microfibrous fuel cells |
| CN101705529A (en) * | 2009-10-29 | 2010-05-12 | 无锡中科光远生物材料有限公司 | Composite superfine fibre membrane of biologic compatible shell core structure and preparation method thereof |
-
2011
- 2011-11-04 CN CN2011103448745A patent/CN102499996A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6350284B1 (en) * | 1998-09-14 | 2002-02-26 | Bionx Implants, Oy | Bioabsorbable, layered composite material for guided bone tissue regeneration |
| US7648665B2 (en) * | 2002-12-23 | 2010-01-19 | Microcell Corporation | Substrate-supported process for manufacturing microfibrous fuel cells |
| CN1727530A (en) * | 2005-07-26 | 2006-02-01 | 天津大学 | Superfine fiber membrane material in core/shell structure, and preparation method |
| CN1733311A (en) * | 2005-08-18 | 2006-02-15 | 同济大学 | The preparation method of the nanofiber of a kind of packaging medicine or somatomedin |
| CN101705529A (en) * | 2009-10-29 | 2010-05-12 | 无锡中科光远生物材料有限公司 | Composite superfine fibre membrane of biologic compatible shell core structure and preparation method thereof |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104027848A (en) * | 2014-06-24 | 2014-09-10 | 中国人民解放军第四军医大学 | Biological scaffold material for periodontium and preparation method thereof |
| CN104027848B (en) * | 2014-06-24 | 2015-10-14 | 中国人民解放军第四军医大学 | A kind of biologic bracket material for periodontal tissue and preparation method thereof |
| CN104491932A (en) * | 2014-12-04 | 2015-04-08 | 上海工程技术大学 | Drug-loaded nanometer anti-adhesion membrane having core/shell structure and preparation method thereof |
| CN104474589A (en) * | 2014-12-23 | 2015-04-01 | 山东国际生物科技园发展有限公司 | Guided tissue regeneration membrane as well as preparation method and application thereof |
| CN104474589B (en) * | 2014-12-23 | 2019-03-12 | 山东国际生物科技园发展有限公司 | A kind of guide tissue regeneration film and the preparation method and application thereof |
| CN110468469A (en) * | 2019-09-03 | 2019-11-19 | 黑龙江中医药大学 | One seed coat layer sandwich layer containing pore-foaming agent carries the preparation method of the coaxial electrostatic spinning silk fiber of medicine |
| EP3981443A1 (en) * | 2020-10-08 | 2022-04-13 | Johann Wolfgang Goethe-Universität Frankfurt | Improved wound dressings, methods for making these, and uses thereof |
| WO2022074142A1 (en) | 2020-10-08 | 2022-04-14 | Johann Wolfgang Goethe-Universität Frankfurt | Improved wound dressings, methods for making these, and uses thereof |
| CN114984295A (en) * | 2022-04-14 | 2022-09-02 | 广东云曌医疗科技有限公司 | Porous nano medical dressing and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | Bioactive materials promote wound healing through modulation of cell behaviors | |
| Yang et al. | Structural and functional design of electrospun nanofibers for hemostasis and wound healing | |
| Li et al. | Review of advances in electrospinning-based strategies for spinal cord regeneration | |
| Sun et al. | Electrospun fibers and their application in drug controlled release, biological dressings, tissue repair, and enzyme immobilization | |
| Gao et al. | Electrospun nanofibers promote wound healing: Theories, techniques, and perspectives | |
| Santoro et al. | Poly (lactic acid) nanofibrous scaffolds for tissue engineering | |
| Choi et al. | Electrospinning strategies of drug-incorporated nanofibrous mats for wound recovery | |
| Nour et al. | Skin wound healing assisted by angiogenic targeted tissue engineering: A comprehensive review of bioengineered approaches | |
| Mohammadian et al. | Drug loading and delivery using nanofibers scaffolds | |
| He et al. | Engineering of biomimetic nanofibrous matrices for drug delivery and tissue engineering | |
| Norouzi et al. | PLGA/gelatin hybrid nanofibrous scaffolds encapsulating EGF for skin regeneration | |
| CN102499996A (en) | Fibrous membrane for non-virus gene treatment and preparation method thereof | |
| Sundaramurthi et al. | Electrospun nanofibers as scaffolds for skin tissue engineering | |
| CN103405809B (en) | Method used for preparing microcarrier/polymer composite scaffold by electro-deposition | |
| US20130177623A1 (en) | Preparation Rich in Growth Factor-Based Fibrous Matrices for Tissue Engeering, Growth Factor Delivery, and Wound Healling | |
| Xiao et al. | Biochemical and biophysical cues in matrix design for chronic and diabetic wound treatment | |
| Duan et al. | Polymeric nanofibers for drug delivery applications: a recent review | |
| US20150030688A1 (en) | Honey and growth factor eluting scaffold for wound healing and tissue engineering | |
| CN102266582A (en) | Preparation method for drug-loaded nanometer fiber medical dressing | |
| CN102397585A (en) | Fiber bracket containing growth factors and preparation method thereof | |
| CN102657898A (en) | Degradable nanofiber anti-adhesive membrane with double-release performance and preparation method of same | |
| de Lima et al. | Electrospinning of hydrogels for biomedical applications | |
| Shi et al. | Adaptive gelatin microspheres enhanced stem cell delivery and integration with diabetic wounds to activate skin tissue regeneration | |
| CN101843578B (en) | Nanofiber membrane carrying anti-tumor photosensitizer and preparation method thereof | |
| CN114108177A (en) | Artificial skin material capable of triggering growth factors to release in stages by photo-thermal method and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120620 |